Perceived genetic risk can affect individuals' physiology more than their actual genetic risk, raising questions about when to disclose such information.
A comprehensive study of genomics malpractice lawsuits showed only a modest increase in recent years, but ASU’s Marchant wouldn't bet on it staying this way in the long term.
Cellworks' technology predicted drug resistance in newly diagnosed patients with myelodysplastic syndromes.
A UK woman sues a hospital for not telling her of her father's genetic testing results, the Guardian reports.
At the National Society of Genetic Counselors annual meeting, a number of clinicians said they conduct their own investigations of variants in clinical lab reports.
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.
The app provides results for 15 genetic conditions in the areas of carrier screening, genetic disease risk, medication response, and health-related traits.
The Wall Street Journal reports on the ethics of genetic testing for aesthetic traits in embryos.
A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.
Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.